September 30, 2016 07:37 AM EDT
R&D
Pharma

Im­muno­Gen's new CEO re­trench­es, ax­ing 65 staffers and look­ing to thin pipeline

John Carroll

Editor & Founder

Im­muno­Gen’s new CEO is done as­sess­ing the com­pa­ny, and one of his first acts will in­volve swing­ing an ax.

The biotech $IMGN is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lon­za looks to de­part cap­sule and health in­gre­di­ents as it un­der­goes re­struc­ture

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Safe­ty con­cerns and tri­al holds for pe­di­atric RSV vac­cines prompt cau­tion from FDA ad­comm

'Se­ri­ous liv­er in­jury' cas­es lead FDA to call for mon­i­tor­ing of Ocali­va pa­tients

Pad­lock share­hold­ers sue Bris­tol My­ers over mile­stone dis­pute af­ter 2016 ac­qui­si­tion

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times